# Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition

> **NCT01603134** · PHASE1 · COMPLETED · sponsor: **IPCA Laboratories Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Fasting State

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT01603134
- **Lead sponsor:** IPCA Laboratories Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603134, "Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01603134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*